סמבליקס 40 מ"ג - Scemblix 40 mg
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | L01EA BCR-ABL tyrosine kinase inhibitors | |||||||||||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| |||||||||||||
| צ×רת ××ª× | פ××× - PER OS | |||||||||||||
| צ×רת ××× ×× | ×××××ת ×צ×פ×ת פ×××, FILM COATED TABLETS ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | |||||||||||||
| ×ת×××× | SCEMBLIX is indicated for the treatment of adult patients with:⢠Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs).⢠Ph+ CML in CP with the T315I mutation | |||||||||||||
| ||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  | |||||||||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ס××××קס 40 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | NOVARTIS PHARMA STEIN AG, SWITZERLAND |
| ×©× ××¢× ×ר×ש×× | NOVARTIS ISRAEL LTD |
| ר×ש××× | ת×ר×× ××ש×: 7/2022. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 06/05/2024 |
ת××× ×ª ×ר×××
השינוי האחרון נעשה בֹ־6 במאי 2024 ב־20:44